Truist Financial Sticks to Its Buy Rating for Legend Biotech (LEGN)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Legend Biotech (LEGN – Research Report) today. The company’s shares ...
BioNTech price target lowered to $151 from $172 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.
DelveInsight Business Research, LLP: TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
Market Inference23h
Investors Are Bullish on Interactive Brokers - Here's What You Need to Know.
One of the standouts of today's morning trading session was Interactive Brokers, which logged a 1.5% performance and ...